258 related articles for article (PubMed ID: 29859377)
1. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder.
Mohebbi M; Dodd S; Dean OM; Berk M
Eur Psychiatry; 2018 Sep; 53():17-22. PubMed ID: 29859377
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
[TBL] [Abstract][Full Text] [Related]
3. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
[TBL] [Abstract][Full Text] [Related]
4. Development of a clinical global impression scale for fatigue.
Targum SD; Hassman H; Pinho M; Fava M
J Psychiatr Res; 2012 Mar; 46(3):370-4. PubMed ID: 22236834
[TBL] [Abstract][Full Text] [Related]
5. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder.
Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
Prim Care Companion J Clin Psychiatry; 2009; 11(1):8-15. PubMed ID: 19333404
[TBL] [Abstract][Full Text] [Related]
6. Construct validity of life chart functioning scales for use in naturalistic studies of bipolar disorder.
Meaden PM; Daniels RE; Zajecka J
J Psychiatr Res; 2000; 34(3):187-92. PubMed ID: 10867113
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials.
Kishi T; Miyake N; Okuya M; Sakuma K; Iwata N
Psychopharmacology (Berl); 2020 Nov; 237(11):3481-3487. PubMed ID: 32767039
[TBL] [Abstract][Full Text] [Related]
8. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
van der Loos ML; Mulder PG; Hartong EG; Blom MB; Vergouwen AC; de Keyzer HJ; Notten PJ; Luteijn ML; Timmermans MA; Vieta E; Nolen WA;
J Clin Psychiatry; 2009 Feb; 70(2):223-31. PubMed ID: 19200421
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.
Calabrese JR; Bowden CL; Sachs GS; Ascher JA; Monaghan E; Rudd GD
J Clin Psychiatry; 1999 Feb; 60(2):79-88. PubMed ID: 10084633
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
13. G.T. MSRS On-Line Calculator Targeting the Early Diagnosis of Mixed Affective States: the Multicenter Study Project Design on the Approbation and Validity of the Three Language Versions of the Rating Scale.
Smirnova D; Vlasov A; Yashikhina A; Astafeva D; Pavlichenko A; Syunyakov T; Tavormina G
Psychiatr Danub; 2023 Oct; 35(Suppl 2):86-93. PubMed ID: 37800208
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of MADRS severity thresholds in patients with bipolar depression.
Thase ME; Harrington A; Calabrese J; Montgomery S; Niu X; Patel MD
J Affect Disord; 2021 May; 286():58-63. PubMed ID: 33677183
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features.
McIntyre RS; Durgam S; Huo J; Kozauer SG; Stahl SM
J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37103915
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
[TBL] [Abstract][Full Text] [Related]
18. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.
Dean OM; Maes M; Ashton M; Berk L; Kanchanatawan B; Sughondhabirom A; Tangwongchai S; Ng C; Dowling N; Malhi GS; Berk M
Clin Psychopharmacol Neurosci; 2014 Dec; 12(3):180-8. PubMed ID: 25598820
[TBL] [Abstract][Full Text] [Related]
19. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder.
Gao K; Su M; Sweet J; Calabrese JR
J Affect Disord; 2019 Feb; 244():9-15. PubMed ID: 30292023
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
